After originally joining closely held RNAi firm Sequitur as a research scientist, Dmitry Samarsky quickly became more and more involved in the company’s business operations. Now Sequitur’s director of technology development, he recently spoke with RNAi News about the firm and its goals for developing RNAi-based therapeutics.
How did you get started in RNAi?
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
